Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Rhea-AI Summary
Arbutus Biopharma (NASDAQ:ABUS) and Genevant Sciences announced a $2.25 billion global settlement with Moderna on March 3, 2026. Moderna will pay $950 million upfront in July 2026 and a $1.3 billion contingent payment tied to an appellate ruling on Section 1498. The settlement includes a court judgment of infringement and no invalidity on four patents and grants Moderna a global non-exclusive license to LNP delivery technology for infectious-disease mRNA vaccines.
Arbutus is evaluating a return of capital to shareholders in Q3 2026 in conjunction with the upfront payment.
Positive
- Upfront payment of $950 million due July 2026
- Contingent $1.3 billion payment tied to Section 1498 appeal
- Court judgment of infringement and no invalidity on four patents
- Global non-exclusive LNP license to Moderna for infectious mRNA vaccines
- Arbutus evaluating return of capital to shareholders in Q3 2026
Negative
- Contingent $1.3 billion depends on a favorable appellate ruling under Section 1498
- License and covenant not to sue grant Moderna broad rights, ending current litigation
- Ongoing Pfizer/BioNTech litigation in the U.S. remains unresolved
Market Reaction – ABUS
Following this news, ABUS has declined 9.61%, reflecting a notable negative market reaction. Argus tracked a peak move of +64.7% during the session. Our momentum scanner has triggered 16 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $4.24. This price movement has removed approximately $96M from the company's valuation. Trading volume is above average at 1.5x the average, suggesting increased trading activity.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
ABUS was modestly higher (+0.21%) with 2 momentum peers (e.g., CRMD, IMNM) also moving up and 3 moving down. Scanner data notes 2 peers up with a median move of ~1.2%, pointing to a mix of stock-specific and broader biotech dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 13 | Earnings & update | Neutral | -5.8% | Q3 2025 financials and pipeline update including ongoing Moderna litigation. |
| Oct 07 | Scientific conference | Positive | -1.1% | Four abstracts accepted for AASLD 2025 with new imdusiran and AB-101 data. |
Recent news events show negative price reactions even to seemingly constructive updates, suggesting a pattern of selling into news.
Over the past few months, Arbutus news has centered on financial updates and scientific visibility. On Nov 13, 2025, Q3 2025 results and a corporate update led to a -5.79% move, despite reporting narrowed losses and ongoing patent actions. On Oct 7, 2025, acceptance of four abstracts for AASLD 2025, featuring data for imdusiran (AB-729) and AB-101, saw a -1.15% reaction. Against this backdrop, today’s large settlement with Moderna marks a major escalation from prior incremental updates.
Market Pulse Summary
The stock is down -9.6% following this news. A negative reaction despite a headline settlement of $2.25 billion would fit a history where Arbutus shares sold off after prior news events. Concerns could include the contingency of the $1.3 billion payment on the Section 1498 appeal and uncertainty around timing and use of proceeds. The market might also reassess residual legal risks, including ongoing Pfizer/BioNTech litigation, and how this outcome reshapes the company’s longer-term business profile.
Key Terms
section 1498 regulatory
lnp medical
mRNA medical
form 8-k regulatory
AI-generated analysis. Not financial advice.
- Moderna to pay Genevant and Arbutus
$950 million upfront and an additional$1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal - If the
$1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industry - Settlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the case
- Genevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Genevant/Arbutus patents and Moderna products, ending all patent-infringement litigation against Moderna arising from its unauthorized use of the technology in its COVID-19 vaccines
- Pfizer/BioNTech litigation is ongoing in the United States following a favorable Markman ruling issued in September 2025; Comirnaty sales represent ~2/3 of global COVID-mRNA vaccine sales to date
- Arbutus announces that it is currently evaluating a return of capital to shareholders for the third quarter of calendar year 2026, in conjunction with the upfront payment
- Roivant will host an investor call to discuss these updates today, March 3, 2026, at 4:45 p.m. ET
BASEL, Switzerland and VANCOUVER, British Columbia, March 03, 2026 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that they have entered into a
As part of the settlement, Moderna will pay Genevant and Arbutus
“We are pleased with this settlement, which allows us to put this lengthy dispute behind us and remain focused on our mission to leverage our world-class nucleic acid delivery systems to bring innovative medicines to people who need them,” said James Heyes, CEO of Genevant Sciences. “At the same time, it is enormously gratifying for the Genevant team to, at long last, be recognized for our pivotal contribution to restoring normalcy around the world in the face of a once-in-a-lifetime pandemic.”
“Nobel laureates, industry executives, and prominent researchers have long recognized that Arbutus scientists changed the drug development landscape when they invented LNP delivery technology, enabling nucleic acids including mRNA to be used for medicines and opening a new world of possibilities,” said Lindsay Androski, President and Chief Executive Officer of Arbutus. “Today, Moderna has finally acknowledged the same. This is a transformative outcome for Arbutus as a company, but more importantly, it is a long-overdue recognition that the COVID-19 vaccines would never have made it to the world without the seminal work of Ian MacLachlan, Ed Yaworski, Lloyd Jeffs, Kieu Lam, Lorne Palmer, and Cory Giesbrecht. Today, above all else, we celebrate – and in the case of Cory, remember – them.”
Investor Conference Call Information
Roivant will host a live conference call and webcast at 4:45 p.m. ET on Tuesday, March 3, 2026, to discuss Genevant’s and Arbutus’
About Genevant Sciences
Genevant Sciences, a subsidiary of Roivant, is a leading nucleic acid delivery company with world-class platforms, a robust lipid nanoparticle (LNP) patent portfolio, and decades of experience and expertise in nucleic acid drug delivery and development. Genevant’s scientists have pioneered LNP delivery of nucleic acids for over 20 years, and Genevant’s LNP platform, which has been studied across more than a dozen discrete product candidates and is the delivery technology behind the first and only approved systemic RNA-LNP product (patisiran), enables a wide array of RNA-based applications, including vaccines, therapeutic protein production, and gene editing. For more information, please visit www.genevant.com.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease. The company is currently developing imdusiran (AB-729) and an oral PD-L1 inhibitor (AB-101) for the treatment of chronic hepatitis B (cHBV) infection. Arbutus is also consulting closely with and supporting its exclusive licensee, Genevant Sciences, to protect and defend its intellectual property, which is the subject of an on-going lawsuit against Pfizer/BioNTech for use of Arbutus’ patented LNP technology in their COVID-19 vaccines. For more information, visit www.arbutusbio.com.
About Roivant
Roivant (Nasdaq: ROIV) is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, visit www.roivant.com.
Forward-Looking Statements and Information
This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward-looking information within the meaning of Canadian securities laws (collectively, forward-looking statements). Forward-looking statements in this press release include, but are not limited to, statements about Arbutus’ plans with respect to ongoing patent litigation matters, including the expected timing thereof and the settlement of the Moderna litigation, and Arbutus’ evaluation of a potential return of capital to its shareholders.
With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things, the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause Arbutus’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: uncertainties associated with litigation generally and patent litigation specifically; economic and market conditions may worsen; and risks related to the sufficiency of Arbutus’ cash resources for its foreseeable and unforeseeable operating expenses and capital expenditures.
A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K, Arbutus’ Quarterly Reports on Form 10-Q and Arbutus’ continuous and periodic disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
Arbutus Biopharma Corporation ir@arbutusbio.com
FAQ
What did Arbutus (ABUS) announce about the Moderna settlement on March 3, 2026?
When will Arbutus receive the upfront payment from Moderna (ABUS)?
What does the contingent $1.3 billion payment mean for ABUS shareholders?
How does the settlement affect Arbutus’ patent claims against Moderna (ABUS)?
Will Arbutus (ABUS) return capital to shareholders after the Moderna settlement?
Does the Moderna settlement end other COVID-mRNA vaccine litigation affecting Arbutus (ABUS)?
